Endurant Capital Management LP Glycomimetics Inc Transaction History

Endurant Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $118,358 - $543,182	-42,271 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $448,072 - $554,595	42,271 New	42,271 $504,000
Q4 2017 Feb 14, 2018	SELL	$10.51 - $17.22 $185,049 - $303,192	-17,607 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $178,534 - $261,463	17,607	17,607 $246,000

36.8M

969K

636K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.